Ariad Pharmaceuticals (ARIA) 8.21 $ARIA Is Ariad

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ariad Pharmaceuticals (ARIA) 8.21 $ARIA

Is Ariad Pharmaceuticals a Cheap Stock?
Todd Campbell, The Motley Fool - Motley Fool - Fri Jul 24, 5:01PM CDT
Source: Ariad Pharmaceuticals Safety concerns fo r Ariad Pharmaceuticals ' Iclusig resulted in a temporary suspension of its sales in 2013, a more stringent prescribing label upon its commercial return in 2014, and a sagging share price that...
ARIA: 8.21 (+0.54)

US Blood Cancer Drug Market & Pipeline Analysis 2015
M2 - Wed Jul 22, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp4cd3/us_blood_cancer) has announced the addition of the "US Blood Cancer Drug Market & Pipeline Analysis 2015" report to their offering. Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs. Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market. Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase. "US Blood Cancer Drug Market & Pipeline Analysis 2015" Report Highlights: - Blood Cancer Incidence & Prevalence - Blood Cancer Drug Market Overview - Blood Cancer Drug Market Dynamics - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs - Majority Drugs in Phase-I Clinical Trials: 128 Drugs - Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis - Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs Key Topics Covered: 1. US Blood Cancer Incidence & Prevalence 2. US Blood Cancer Drug Market Overview 3. US Blood Cancer Drug Market Dynamics 4. US Blood Cancer Drug Market Future Prospects 5. Mechanism of Blood Cancer Therapeutics 6. Leukemia Drug Clinical Pipeline by Company & Phase 7. Marketed Leukemia Drug Clinical Insight 8. Lymphoma Drug Clinical Pipeline by Company & Phase 9. Marketed Lymphoma Drug Clinical Insight 10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase 11. Marketed Multiple Myeloma Drug Clinical Insight 12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase 13. Marketed Multiple Blood Cancer Drug Clinical Insight 14. Competitive Landscape - ARIAD Pharmaceuticals - Actelion Pharmaceuticals - Amgen - Astellas Pharma - Baxter BioScience - Bayer HealthCare Pharmaceuticals Inc. - Biogen Idec - Bristol-Myers Squibb - CASI Pharmaceuticals - Celera Genomics Group - Celgene Corporation - Eisai Co Ltd - Genmab - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Millennium Pharmaceuticals - Nova Laboratories - Novartis - Onxeo SA - Onyx Pharmaceuticals - Otsuka Pharmaceutical - Pfizer - Roche - SRI International - Scripps Clinic - Seattle Genetics - Southern Research Institute - Tekmira Pharmaceuticals Corporation - Teva Pharmaceutical Industries - Yakult Honsha For more information visit http://www.researchandmarkets.com/research/hp...ood_cancer
BIIB: 318.14 (+8.71), TKMR: 10.37 (+0.07), AMGN: 173.17 (+7.63), GSK: 41.70 (+0.10), BMY: 64.50 (+0.20), CASI: 1.60 (+0.01), JNJ: 99.12 (+0.84), GILD: 112.38 (+1.84), TEVA: 71.13 (-0.87), ARIA: 8.21 (+0.54), NVS: 102.73 (+1.19), CELGZ: 2.03 (+0.03)

ARIAD to Webcast Conference Call on Second Quarter 2015 Financial Results
Business Wire - Wed Jul 22, 6:34AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2015 financial results on Wednesday, August 5, 2015, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
ARIA: 8.21 (+0.54)

Equity Coverage on Biotechnology -- Aeterna Zentaris, Ariad Pharma, AVEO Pharma, Aduro BioTech, and 22nd Century Group
PR Newswire - Thu Jul 16, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Aeterna Zentaris Inc. (NASDAQ: AEZS), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Aduro BioTech Inc. (NASDAQ: ADRO), and 22nd Century Group Inc. (AMEX: XXII). Free research report on Aeterna Zentaris can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AEZS On Wednesday, July 15, 2015, the NASDAQ Composite ended at 5,098.94, down 0.12%, the Dow Jones Industrial Average edged 0.02% lower, to finish the day at 18,050.17, and the S&P 500 closed at 2,107.40, down 0.07%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
XXII: 0.76 (+0.01), ADRO: 26.86 (+0.46), AVEO: 1.52 (+0.01), AEZS: 0.20 (+0.01), ARIA: 8.21 (+0.54)

United States Breast Cancer Therapy Market Opportunity Analysis
PR Newswire Europe - Wed Jul 15, 10:33AM CDT
Research and Markets(http://www.researchandmarkets.com/research/vk2qxr/us_breast_cancer [http://www.researchandmarkets.com/research/vk2qxr/us_breast_cancer]) has announced the addition of the "US Breast Cancer Therapy Market Opportunity Analysis" [http://www.researchandmarkets.com/research/vk2qxr/us_breast_cancer] report to their offering.
BMRN: 144.80 (+0.48), NAVB: 1.72 (-0.03), A: 40.30 (+0.69), MRK: 57.26 (+0.27), INCY: 105.70 (+1.33), ARIA: 8.21 (+0.54), NKTR: 12.93 (+0.51), DYAX: 25.22 (+0.49), NVS: 102.73 (+1.19), CELGZ: 2.03 (+0.03)

Critical Alerts For FireEye, Ariad Pharmaceuticals, ACADIA Pharmaceuticals, Esperion Therapeutics and Humana Released By InvestorsObserver
PR Newswire - Wed Jul 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, ARIA, ACAD, ESPR and HUM.
ESPR: 69.37 (-2.28), ACAD: 49.28 (+1.72), FEYE: 45.65 (-0.70), ARIA: 8.21 (+0.54), HUM: 184.29 (+0.38)

Orphan Drug Product Candidate Development Provides Revolutionary Solutions for Treatment of Severe Injuries and Innovative Therapies for Rare Diseases & Conditions
PR Newswire - Wed Jul 15, 7:15AM CDT
As modern biotechnology continues to provide breakthrough products and technologies to combat debilitating rare diseases, treat severe injuries and offer therapeutic treatments for many areas of various medical conditions, today's leading biotech & biopharmaceutical companies such as Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), Celldex Therapeutics, Inc. (NASDAQ: CLDX) and Receptos, Inc. (NASDAQ: RCPT) race to introduce the newest technologies and products that help improve the lives and overall health of patients worldwide.
NVIV: 15.03 (+0.24), CLDX: 24.70 (+0.39), RCPT: 227.95 (+0.86), EPRS: 7.00 (+0.62), ARIA: 8.21 (+0.54), CELG: 135.63 (+3.07)

BUYINS.NET: ARIA SqueezeTrigger Price is $7.98. There is $364,614,804 That Short Sellers Still Need To Cover.
M2 - Mon Jul 13, 12:00PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring ARIAD Pharmaceuticals Inc (NASDAQ:ARIA) in real time and just received an alert that ARIA is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 45350100 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $7.98. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ARIA: 8.21 (+0.54)

Critical Alerts For Alibaba, Ariad Pharmaceuticals, Splunk, Receptos Inc. and Yelp Released By InvestorsObserver
PR Newswire - Wed Jul 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BABA, ARIA, SPLK, RCPT and YELP.
RCPT: 227.95 (+0.86), SPLK: 70.65 (+0.05), ARIA: 8.21 (+0.54), YELP: 33.46 (-0.27), BABA: 80.40 (-1.00)

BUYINS.NET: ARIA SqueezeTrigger Price is $7.98. There is $358,595,622 That Short Sellers Still Need To Cover.
M2 - Tue Jun 30, 11:31AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring ARIAD Pharmaceuticals Inc (NASDAQ:ARIA) in real time and just received an alert that ARIA is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 44629200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $7.98. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ARIA: 8.21 (+0.54)

ARIAD (ARIA) Presents Favorable Long-Term Data on Iclusig - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 15, 3:25PM CDT
ARIAD Pharmaceuticals (ARIA) presented encouraging long-term follow-up results from the pivotal phase II study (PACE) on Iclusig, at the European Hematology Association.
GILD: 112.38 (+1.84), ARIA: 8.21 (+0.54), BMY: 64.50 (+0.20), NVS: 102.73 (+1.19)

Look for Shares of Ariad Pharmaceuticals to Potentially Rebound after Yesterday's 2.42% Sell Off
Comtex SmarTrend(R) - Fri Jun 12, 4:57PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.53 to a high of $8.94. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $8.70 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 8.21 (+0.54)

ARIAD's Iclusig delivers long-term therapeutic benefit in blood cancer patients
Seeking Alpha - at Seeking Alpha - Fri Jun 12, 10:43AM CDT

ARIA: 8.21 (+0.54)

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
Business Wire - Fri Jun 12, 10:15AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of approximately 3.5 years for chronic phase CML (CP-CML) patients and a median follow-up of approximately 2.9 years in all patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options. Responses have been maintained long-term in CP-CML patients. Eighty-three percent (83%) of CP-CML patients who achieved a major cytogenetic response (MCyR) are estimated to remain in MCyR at three years.
ARIA: 8.21 (+0.54)

Ariad Pharmaceuticals Shares Up 23.6% Since SmarTrend's Buy Recommendation (ARIA)
Comtex SmarTrend(R) - Fri Jun 12, 9:48AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 6 months, Ariad Pharmaceuticals has returned 23.60% as of today's recent price of $8.80.
ARIA: 8.21 (+0.54)

Critical Alerts For Hewlett Packard, Illumina, Bitauto Holdings, GW Pharmaceuticals and Ariad Pharmaceuticals Released By InvestorsObserver
PR Newswire - Thu Jun 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for HPQ, ILMN, BITA, GWPH and ARIA.
GWPH: 113.65 (+1.54), ILMN: 218.01 (+0.74), ARIA: 8.21 (+0.54), HPQ: 30.25 (unch), BITA: 39.78 (-0.51)

ARIAD partners with Paladin for commercial distribution of Iclusig (Ponatinib) in Canada
M2 - Thu Jun 11, 5:01AM CDT
Oncology company ARIAD Pharmaceuticals (NasdaqGS:ARIA) revealed on Wednesday that it has grant ed exclusive rights to distribute Iclusig (as ponatinib hydrochloride) in Canada for its newly approved indications to Paladin Labs, an operating company of Endo International.
ARIA: 8.21 (+0.54)

Cancer Stocks: 2 to Sell, 1 to Buy
George Budwell, The Motley Fool - Motley Fool - Wed Jun 10, 9:05AM CDT
Cancer stocks in general have been on absolute fire this year due to the confluence of new regulatory pathways leading to quicker regulatory approvals, as well as a number of stunning clinical successes for traditionally hard-to-treat malignancies. ...
ADXS: 17.33 (+0.06), PFE: 35.25 (+0.91), MRK: 57.26 (+0.27), AZN: 32.85 (+0.14), BMY: 64.50 (+0.20), ARIA: 8.21 (+0.54), NVS: 102.73 (+1.19), EXEL: 5.48 (+0.04)

ARIAD and Paladin Announce Commercial Distribution Agreement for Iclusig (Ponatinib) in Canada
Business Wire - Wed Jun 10, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Paladin Labs Inc., an operating company of Endo International plc (NASDAQ: ENDP) (TSX: ENL), today announced that ARIAD has granted Paladin exclusive rights to distribute Iclusig(TM) (as ponatinib hydrochloride) in Canada for its newly approved indications. Paladin is focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.
ENDP: 87.86 (+2.05), ENL.TO: 113.67 (+1.89), ARIA: 8.21 (+0.54)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 328

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 258

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 459

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 157

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 121

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 332

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 509

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 250

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading

Top 5 Most Recently Viewed Articles

Atlanticus Holdings Celebrates Substantial Year-End Growth

Updated Category News Views 176

Impressive Financial Results for Atlanticus Holdings Atlanticus Holdings Corporation (NASDAQ: ATLC), known for empowering financial inclusivity through innovative technology, has reported remarkable achievements in its financial results for the fourth quarter and the full year ended December 31, 2024. The company served an impressive total of 3.7 million accounts,...

Continue Reading
Jonas Warrer Expands Stake in Gentoo Media: Key Insights

Updated Category News Views 262

Jonas Warrer's Strategic Move in Gentoo Media Holdings Recent transactions in the stock market have captivated the attention of many investors, particularly when they involve significant figures in the industry. One such notable event occurred when Jonas Warrer, CEO and primary insider of Gentoo Media, made headlines by acquiring a substantial number of shares in his own...

Continue Reading
Venture Global Inc. Faces Class Action Over Investor Losses

Updated Category News Views 233

Venture Global Inc. Investors Advised on Class Action For investors in Venture Global Inc. seeking justice, significant legal developments have unfolded. The company, known for its ambitious initiatives in the liquefied natural gas sector, is currently facing serious allegations in a class action lawsuit. For those who lost money in their investments, it's crucial to...

Continue Reading
Global Roaming Tariff Market Expected to Hit USD 140.3 Billion

Updated Category News Views 329

Overview of the Roaming Tariff Market Growth The Roaming Tariff Market has entered an exciting phase, anticipated to soar to USD 140.3 billion by 2032, after reaching USD 77.5 billion in 2023. Such growth, at a compound annual growth rate (CAGR) of 6.83% from 2024 to 2032, is invigorated by the widespread expansion of 5G technology and increasing global travel demand. Key...

Continue Reading
Investing Insights: Analyzing Charles Schwab's Market Position

Updated Category News Views 263

Understanding the Recent Shift in Charles Schwab's Market Position Charles Schwab's short percent of float has recently experienced a significant increase, rising by 67.5% as indicated by the latest reports. Currently, there are 22.74 million shares sold short, which accounts for 1.34% of the total regular shares available for trading. With this short interest, traders...

Continue Reading